

## CORRECTION


# Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF- $\beta$ RI inhibitor galunisertib

Gianluigi Giannelli, Armando Santoro, Robin K. Kelley, Ed Gane, Valerie Paradis, Ann Cleverly, Claire Smith, Shawn T. Estrem, Michael Man, Shuaicheng Wang, Michael M. Lahn, Eric Raymond, Karim A. Benhadji, Sandrine Faivre

There is an error in affiliation 2 for the second author Armando Santoro. The correct affiliation 2 is: Humanitas Clinical and Research Center-IRCCS, Humanitas Cancer Center, Milan, Italy. An additional affiliation is also missing for the second author. Armando Santoro is also affiliated with Humanitas University, Department of Biomedical Sciences, Milan, Italy.

## Reference

1. Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, et al. (2020) Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF- $\beta$ RI inhibitor galunisertib. PLOS ONE 15(3): e0222259. <https://doi.org/10.1371/journal.pone.0222259> PMID: 32210440



## OPEN ACCESS

**Citation:** Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, et al. (2021)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF- $\beta$ RI inhibitor galunisertib. PLoS ONE 16(6): e0253671. <https://doi.org/10.1371/journal.pone.0253671>

**Published:** June 17, 2021

**Copyright:** © 2021 Giannelli et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.